CSIMarket
 
Aclarion Inc   (ACON)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $0.4000 $0.05 14.384%
Day's High: $0.46 Week Perf: 8.4 %
Day's Low: $ 0.34 30 Day Perf: -77.78 %
Volume (M): 12,629 52 Wk High: $ 37.92
Volume (M$): $ 5,052 52 Wk Avg: $7.69
Open: $0.36 52 Wk Low: $0.27



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Aclarion Inc
Aclarion Inc is a technology consulting company that offers a wide range of services related to software development and IT consulting. They specialize in helping businesses leverage technology to improve their efficiency, productivity, and overall performance. Aclarion Inc works with clients from various industries and provides customized solutions to meet their specific needs. Their team of experienced professionals offers expertise in areas such as mobile app development, web development, cloud computing, data analysis, and cybersecurity. Aclarion Inc aims to deliver innovative and reliable solutions that help businesses stay competitive in the ever-evolving digital landscape.


   Company Address: 8181 Arista Place Broomfield 80021 CO
   Company Phone Number: 275-2266   Stock Exchange / Ticker: NASDAQ ACON
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Financing Agreement

Aclarion Announces Pricing of $3.0 Million Public Offering Amidst Financial Concerns

Published Mon, Feb 26 2024 2:15 PM UTC

Aclarion, Inc. Announces Pricing of Public Offering Amidst Financial Concerns
BROOMFIELD, CO ?? Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company specializing in leveraging biomarkers and proprietary augmented intelligence algorithms, recently announced the pricing of its public offering of 5,175,000 units. Each unit consists of one share of common st...

Partnership

Aclarion Announces Successful Financings and Introduces CLARITY Trial to Continue Advancements in Surgical Decision-making

Published Mon, Feb 5 2024 1:00 PM UTC

Aclarion, a leading medical technology company, has recently revealed its plans to launch the CLARITY trial, a pivotal multicenter, prospective, randomized study. This trial aims to further validate the superior surgical outcomes achieved by utilizing their innovative Nociscan technology in surgical decision-making. Additionally, the company has successfully secured new fina...

Partnership

Revolutionizing Spine Surgeries: Aclarion Inc.'s Strategic Partnership Accelerates Revenue Growth

Published Mon, Jan 8 2024 1:01 PM UTC

Aclarion Inc., a leading provider of surgical decision support technology, has recently forged a strategic partnership agreement with ATEC (Alpha Technology Company). The primary objective of this collaboration is to expedite the commercialization of Aclarion?s revolutionary NociScan platform and enhance spine surgery outcomes through ATEC's AlphaInformatiX platform. This gr...

Shares

Aclarion Empowers Market Value with 1-for-16 Reverse Stock Split

Published Tue, Jan 2 2024 5:00 PM UTC

Aclarion Announces Reverse Stock Split to Enhance Value and Attract Investors
BROOMFIELD, CO, Jan. 02, 2024 - Aclarion, Inc. (Nasdaq: ACON, ACONW), a leading healthcare technology company specializing in identifying the location of chronic low back pain, has revealed its plans to complete a 1-for-16 reverse stock split of its common stock. This strategic decision aims to...

Aclarion Inc

Revised headline: Aclarion Inc's Revenue Sees Steady Growth in Q3 2023, Boosting Market Position2.



The stock market is a dynamic arena where investors scrutinize the financial performance of different companies to make informed investment decisions. Aclarion Inc, a Medical Laboratories company, has recently shared its fiscal results for the most recent reporting period. In this article, we will delve into the interesting facts surrounding the company's performance, analyzing its revenue growth, net shortfall, accounts receivable, and provide insights into its future prospects.
Revenue Growth and Market Position:
During the most recent fiscal period, Aclarion Inc reported reaching a flat valuation of $0.00 per share, which was consistent with the previous year's figure. However, it's worth noting that the company's revenue increased moderately by 4.626% to $0.02 million from the corresponding period a year ago. This positive revenue growth places Aclarion Inc in a favorable position within the Medical Laboratories industry, which witnessed an overall 4.27% top-line growth during the same period. Sequentially, Aclarion Inc's revenue advanced by 11.674% from the preceding financial reporting period, demonstrating its ability to sustain growth and expand its market share.






 

Aclarion Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com